Stereotaxis (STXS): Price and Financial Metrics

Stereotaxis (STXS): $1.84

-0.06 (-3.16%)

POWR Rating

Component Grades














  • STXS scores best on the Stability dimension, with a Stability rank ahead of 54.17% of US stocks.
  • The strongest trend for STXS is in Growth, which has been heading down over the past 179 days.
  • STXS's current lowest rank is in the Growth metric (where it is better than 8.14% of US stocks).

STXS Stock Summary

  • For STXS, its debt to operating expenses ratio is greater than that reported by merely 18.28% of US equities we're observing.
  • STXS's price/sales ratio is 7.99; that's higher than the P/S ratio of 81.94% of US stocks.
  • The volatility of Stereotaxis Inc's share price is greater than that of 81.97% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Stereotaxis Inc, a group of peers worth examining would be BMRA, VRNS, FIVN, ZUO, and HCAT.
  • Visit STXS's SEC page to see the company's official filings. To visit the company's web site, go to

STXS Valuation Summary

  • STXS's price/sales ratio is 15.8; this is 39.21% higher than that of the median Healthcare stock.
  • STXS's EV/EBIT ratio has moved down 83.7 over the prior 208 months.
  • Over the past 208 months, STXS's price/sales ratio has gone down 2.8.

Below are key valuation metrics over time for STXS.

Stock Date P/S P/B P/E EV/EBIT
STXS 2021-08-31 15.8 14.4 -76.8 -89.3
STXS 2021-08-30 14.2 13.0 -69.0 -79.4
STXS 2021-08-27 14.0 12.7 -67.7 -77.8
STXS 2021-08-26 14.0 12.7 -67.9 -78.1
STXS 2021-08-25 14.1 12.9 -68.5 -78.9
STXS 2021-08-24 14.7 13.4 -71.4 -82.5

STXS Growth Metrics

    Its 2 year revenue growth rate is now at -11.21%.
  • Its 5 year net cashflow from operations growth rate is now at -61.1%.
  • The 4 year net income to common stockholders growth rate now stands at 9.73%.
STXS's revenue has moved up $4,124,408 over the prior 52 months.

The table below shows STXS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 35.02086 -2.945911 -12.06065
2021-09-30 33.60519 -0.582029 -9.889141
2021-06-30 33.20232 -0.445619 -6.847937
2021-03-31 29.49635 -1.651173 -7.565574
2020-12-31 26.63003 -3.511772 -8.01588
2020-09-30 26.6981 -5.734686 -7.937102

STXS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • STXS has a Quality Grade of B, ranking ahead of 89.02% of graded US stocks.
  • STXS's asset turnover comes in at 0.581 -- ranking 75th of 186 Medical Equipment stocks.
  • FONR, SMLR, and KIDS are the stocks whose asset turnover ratios are most correlated with STXS.

The table below shows STXS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.581 0.676 -2.014
2021-03-31 0.516 0.684 -1.715
2020-12-31 0.504 0.712 -1.512
2020-09-30 0.536 0.708 -1.279
2020-06-30 0.565 0.786 -0.976
2020-03-31 0.739 0.795 -0.864

STXS Stock Price Chart Interactive Chart >

Price chart for STXS

STXS Price/Volume Stats

Current price $1.84 52-week high $10.09
Prev. close $1.90 52-week low $1.72
Day low $1.83 Volume 251,500
Day high $1.91 Avg. volume 420,541
50-day MA $2.12 Dividend yield N/A
200-day MA $4.46 Market Cap 137.38M

Stereotaxis (STXS) Company Bio

Stereotaxis Inc. designs, manufactures, and markets advanced cardiology instrument control system for use in the cath lab that is used in the treatment of coronary artery disease and arrhythmias. The Company markets Stereotaxis System in the United States and Europe.

STXS Latest News Stream

Event/Time News Detail
Loading, please wait...

STXS Latest Social Stream

Loading social stream, please wait...

View Full STXS Social Stream

Latest STXS News From Around the Web

Below are the latest news stories about Stereotaxis Inc that investors may wish to consider to help them evaluate STXS as an investment opportunity.

Stereotaxis to Present at Upcoming Investor Conferences

ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, chairman and CEO, will present at three investor conferences in the first quarter 2022.

GlobeNewswire | February 14, 2022

Stereotaxis to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2021 fourth quarter and full year ended December 31, 2021 on Thursday, March 3, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company’s results and corporate developments

Yahoo | February 14, 2022

Roubaix Capital, LLC Buys Treace Medical Concepts Inc, Alpha Teknova Inc, EnerSys, Sells Rogers ...

Investment company Roubaix Capital, LLC (Current Portfolio) buys Treace Medical Concepts Inc, Alpha Teknova Inc, EnerSys, Xometry Inc, First Citizens BancShares Inc, sells Rogers Corp, Alliance Data Systems Corp, Hayward Holdings Inc, Gates Industrial Corp PLC, Aspen Aerogels Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Roubaix Capital, LLC.

Yahoo | January 28, 2022

Fuwai Central China Cardiovascular Hospital Becomes First to Offer Advanced Robotic Treatment for Heart Rhythm Disorders in Central China

ST. LOUIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Fuwai Central China Cardiovascular Hospital has become the first in central China to establish a robotic electrophysiology program with installation of Stereotaxis’ Robotic Magnetic Navigation technology. Chief physicians for arrhythmia treatment, Dr. Chen Ke and Dr. Song Weifeng, successfully performed their first ro

Yahoo | January 27, 2022

HonorHealth Scottsdale Shea Medical Center Builds Advanced Robotic Program to Treat Heart Rhythm Disorders

ST. LOUIS, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that HonorHealth has established a robotic electrophysiology program as part of its Cardiovascular Center of Excellence at HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona. HonorHealth is among the first in the nation to offer the Genesis Robotic Magnetic Navigation (RMN) system to patients receiving minim

Yahoo | January 25, 2022

Read More 'STXS' Stories Here

STXS Price Returns

1-mo -4.66%
3-mo -50.40%
6-mo -70.32%
1-year -80.77%
3-year -34.05%
5-year 217.24%
YTD -70.32%
2021 21.81%
2020 -3.78%
2019 389.36%
2018 35.13%
2017 23.10%

Continue Researching STXS

Want to see what other sources are saying about Stereotaxis Inc's financials and stock price? Try the links below:

Stereotaxis Inc (STXS) Stock Price | Nasdaq
Stereotaxis Inc (STXS) Stock Quote, History and News - Yahoo Finance
Stereotaxis Inc (STXS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8234 seconds.